Pharmacologic Aspects of Eradication Therapy for Helicobacter pylori Infection
作者： Takahisa Furuta , David Y. Graham
DOI: 10.1016/J.GTC.2010.08.007
关键词: Medicine 、 Amoxicillin 、 Antibiotics 、 CYP2C19 、 Helicobacter pylori 、 Metronidazole 、 Tetracycline 、 Pharmacology 、 Antimicrobial 、 Clarithromycin
摘要: The commonly used regimens for the eradication of Helicobacter pylori infection consist administration proton pump inhibitors (PPIs) and 1 to 3 antimicrobial agents, such as amoxicillin, clarithromycin, metronidazole, fluoroquinolone, or tetracycline. Each agent has its own pharmacologic characteristics. PPIs are metabolized by cytochrome P450 2C19 (CYP2C19), which is polymorphic. CYP2C19 genotypic differences in pharmacokinetics pharmacodynamics influence rates H PPI-containing regimens. Amoxicillin a time-dependent antibiotic, whereas tetracycline, fluoroquinolone not. plasma half-life agents also differs among these antibiotics. To achieve consistently high rates, must be designed based on good understanding resistance patterns bacteria characteristics therapy.
elsevier.com
sci-hub.se 参考文章(69)
Kyoichi Ohashi, Takahisa Furuta, Mitsushige Sugimoto, Naohito Shirai, Takashi Ishizaki, Fang Xiao, Misako Takashita, Masayoshi Kajimura, High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepato-gastroenterology. ,vol. 50, pp. 2274- 2278 ,(2003)
Francisco C. Ramirez, David Y. Graham, Ginger M. Lew, Robert M. Genta, Mohammad T. Al‐Assi, Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. The American Journal of Gastroenterology. ,vol. 89, pp. 1203- 1205 ,(1994) , 10.1111/J.1572-0241.1994.TB10276.X
Elaine M. Hylek, Oral anticoagulants: Pharmacologic issues for use in the elderly Clinics in Geriatric Medicine. ,vol. 17, pp. 1- 13 ,(2001) , 10.1016/S0749-0690(05)70102-6
S.M. de Morais, G.R. Wilkinson, J. Blaisdell, K. Nakamura, U.A. Meyer, J.A. Goldstein, The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. Journal of Biological Chemistry. ,vol. 269, pp. 15419- 15422 ,(1994) , 10.1016/S0021-9258(17)40694-6
K G Tolman, K C Marsh, S C Quigley, J E Lamm, M J Johnson, J H Cavanaugh, S W Sanders, J L Ferrero, D J Anderson, B A Bopp, Metabolism and disposition of clarithromycin in man. Drug Metabolism and Disposition. ,vol. 18, pp. 441- 446 ,(1990)
Takahisa Furuta, Yukiko Sagehashi, Naohito Shirai, Mitsushige Sugimoto, Akiko Nakamura, Makoto Kodaira, Kazumi Kenmotsu, Makoto Nagano, Tohru Egashira, Koji Ueda, Masao Yoneyama, Kyoichi Ohashi, Takashi Ishizaki, Akira Hishida, Influence of CYP2C19 Polymorphism and Helicobacter pylori Genotype Determined From Gastric Tissue Samples on Response to Triple Therapy for H pylori Infection Clinical Gastroenterology and Hepatology. ,vol. 3, pp. 564- 573 ,(2005) , 10.1016/S1542-3565(04)00779-7
J Versalovic, D Shortridge, K Kibler, M V Griffy, J Beyer, R K Flamm, S K Tanaka, D Y Graham, M F Go, Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrobial Agents and Chemotherapy. ,vol. 40, pp. 477- 480 ,(1996) , 10.1128/AAC.40.2.477
Venodhar R. Julapalli, David Y. Graham, Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer. Digestive Diseases and Sciences. ,vol. 50, pp. 1185- 1193 ,(2005) , 10.1007/S10620-005-2758-7
Mateusz Kurzawski, Barbara Gawrońska-Szklarz, Joanna Wrześniewska, Andrzej Siuda, Teresa Starzyńska, Marek Droździk, Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. European Journal of Clinical Pharmacology. ,vol. 62, pp. 877- 880 ,(2006) , 10.1007/S00228-006-0183-2
C. Hassan, V. De Francesco, A. Zullo, G. Scaccianoce, D. Piglionica, E. Ierardi, C. Panella, S. Morini, Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. Alimentary Pharmacology & Therapeutics. ,vol. 18, pp. 641- 646 ,(2003) , 10.1046/J.1365-2036.2003.01694.X